Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Research on drug interactions and efficacy optimization of combined medication for elderly patients with ischemic cerebrovascular disease in Guangxi Zhuang Autonomous Region.

Created on 12 Jul 2026

Authors

Jiaguan Chen, Weili Li, Nengzhen Pan, Zhanxi Liu, Zhiling Cai

Published in

Pakistan journal of pharmaceutical sciences. Volume 39. Issue 9. Pages 2630-2637.

Abstract

The incidence of ischemic cerebrovascular disease (ICVD) among the elderly in Guangxi is higher than the national average. The Zhuang ethnic group, the dominant ethnic group in the region, has unique genetic backgrounds and medication habits, often taking antiplatelet drugs and digestive system medications simultaneously, increasing the risk of drug interactions.
To explore combined medication characteristics and optimize regimens for elderly ICVD patients in Guangxi, focusing on ethnic genetic differences and drug interactions.
A retrospective analysis included 2135 elderly ICVD patients (873 Zhuang, 1262 Han) from 2019-2022; 807 patients received a prospective stratified regimen (2023). CYP2C19 genotypes, platelet function, and clinical outcomes were analyzed.
Zhuang patients had a higher CYP2C19*3 allele frequency (28.7% vs 19.2%, P=0.004) and clopidogrel resistance rate (34.1% vs 14.7%, P<0.001). The aspirin +clopidogrel +omeprazole regimen (51.3% usage) increased stroke recurrence risk (HR=2.81). The stratified regimen boosted efficacy to 89.2%, reduced severe bleeding by 57.3%, and lowered 6-month recurrence rate from 15.7% to 8.3% (all P<0.01).
Elderly Zhuang ICVD patients show distinct CYP2C19 genotypes associated with clopidogrel resistance. A genotype-liver/kidney function stratified regimen improves efficacy and safety, supporting precision medication in ethnic minority areas.

PMID:
42436620
Bibliographic data and abstract were imported from PubMed on 12 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement